{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:55:24Z","timestamp":1785390924620,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007405","name":"Hjerteforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004954","name":"Augustinus Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Persons living with HIV (PLWH) may have increased incidence of cardiovascular events and longer QTc intervals than uninfected persons. We aimed to investigate the incidence and risk factors of de novo major electrocardiogram (ECG) abnormalities and QTc prolongation in well-treated PLWH. We included virologically suppressed PLWH without major ECG abnormalities, who attended the 2-year follow-up in the Copenhagen comorbidity in HIV infection (COCOMO) study. ECGs were categorized according to Minnesota Code Manual. We defined de novo major ECG abnormalities as new major Minnesota Code Manual abnormalities. Prolonged QTc was defined as QTc\u2009&gt;\u2009460\u00a0ms in females and QTc\u2009&gt;\u2009450\u00a0ms in males. Of 667 PLWH without major ECG abnormalities at baseline, 34 (5%) developed de novo major ECG abnormalities after a median of 2.3\u00a0years. After adjustment, age (RR: 1.57 [1.08\u20132.28] per decade older), being underweight (RR: 5.79 [1.70\u201319.71]), current smoking (RR: 2.34 [1.06\u20135.16]), diabetes (RR: 3.89 [1.72\u20138.80]) and protease inhibitor use (RR: 2.45 [1.27\u20134.74) were associated with higher risk of getting de novo major ECG abnormalities. Of PLWH without prolonged QTc at baseline, only 11 (1.6%) participants developed de novo prolonged QTc. Five percent of well-treated PLWH acquired de novo major ECG abnormalities and protease inhibitor use was associated with more than twice the risk of de novo major ECG abnormalities. De novo prolonged QTc was rare and did not seem to constitute a problem in well-treated PLWH.<\/jats:p>","DOI":"10.1038\/s41598-021-00290-x","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T10:04:42Z","timestamp":1634810682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["De novo electrocardiographic abnormalities in persons living with HIV"],"prefix":"10.1038","volume":"11","author":[{"given":"Andreas D.","family":"Knudsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Bille","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda Teresa","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"H\u00f8gh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Benfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Gerstoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus F.","family":"Kofoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne D.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"issue":"21","key":"290_CR1","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/j.jacc.2012.02.024","volume":"59","author":"ZH Tseng","year":"2012","unstructured":"Tseng, Z. H. et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J. Am. Coll. Cardiol. 59(21), 1891\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2012.02.024 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"290_CR2","doi-asserted-by":"crossref","unstructured":"Shah, A. S. V., Stelzle, D., Ken Lee, K., Beck, E. J., Alam, S., Clifford, S., et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living with HIV Systematic Review and Meta-analysis. Vol. 138, Circulation 1100\u20131112 (Lippincott Williams and Wilkins, 2018).","DOI":"10.1161\/CIRCULATIONAHA.117.033369"},{"key":"290_CR3","first-page":"66","volume":"60","author":"R Auer","year":"2012","unstructured":"Auer, R. et al. Association of major and minor ECG abnormalities with coronary heart disease events. J. Am. Med. Assoc. 60, 66 (2012).","journal-title":"J. Am. Med. Assoc."},{"key":"290_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1161\/JAHA.116.004954","volume":"6","author":"C Iribarren","year":"2017","unstructured":"Iribarren, C., Round, A. D., Lu, M., Okin, P. M. & McNulty, E. J. Cohort study of ECG left ventricular hypertrophy trajectories: Ethnic disparities, associations with cardiovascular outcomes, and clinical utility. J. Am. Heart Assoc. 6, 66 (2017).","journal-title":"J. Am. Heart Assoc."},{"issue":"14","key":"290_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAD.0000000000002327","volume":"33","author":"AD Knudsen","year":"2019","unstructured":"Knudsen, A. D. et al. Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV. AIDS 33(14), 1 (2019).","journal-title":"AIDS"},{"key":"290_CR6","first-page":"66","volume":"6","author":"N Friis-Moller","year":"2007","unstructured":"Friis-Moller, N. et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 6, 66 (2007).","journal-title":"N. Engl. J. Med."},{"key":"290_CR7","first-page":"66","volume":"6","author":"SD Holmberg","year":"2002","unstructured":"Holmberg, S. D. et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 6, 66 (2002).","journal-title":"Lancet"},{"key":"290_CR8","first-page":"66","volume":"6","author":"F D\u2019Ascenzo","year":"2012","unstructured":"D\u2019Ascenzo, F. et al. Acute coronary syndromes in human immunodeficiency virus patients: A meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur. Heart J. 6, 66 (2012).","journal-title":"Eur. Heart J."},{"issue":"6","key":"290_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jinf.2006.11.001","volume":"54","author":"P Chinello","year":"2007","unstructured":"Chinello, P. et al. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. J. Infect. 54(6), 597\u2013602 (2007).","journal-title":"J. Infect."},{"issue":"10","key":"290_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/jce.13032","volume":"27","author":"AM Abdelhady","year":"2016","unstructured":"Abdelhady, A. M. et al. Efavirenz inhibits the human Ether-A-Go-Go Related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers. J. Cardiovasc. Electrophysiol. 27(10), 1206\u20131213 (2016).","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"290_CR11","unstructured":"Arizona Center for Education and Research on Therapeutics. Combined List of Drugs that Prolong QT AND\/OR Cause Torsades DE Pointes (TDP). [cited 2019 Jun 6]. https:\/\/crediblemeds.org\/"},{"issue":"1","key":"290_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1186\/s12879-016-2026-9","volume":"16","author":"A Ronit","year":"2016","unstructured":"Ronit, A. et al. Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. BMC Infect. Dis. 16(1), 713. https:\/\/doi.org\/10.1186\/s12879-016-2026-9 (2016).","journal-title":"BMC Infect. Dis."},{"key":"290_CR13","first-page":"66","volume":"6","author":"T Unger","year":"2020","unstructured":"Unger, T. et al. International society of hypertension global hypertension practice guidelines. Hypertension 6, 66 (2020).","journal-title":"Hypertension"},{"key":"290_CR14","first-page":"66","volume":"6","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. ESC\/ESH guidelines for themanagement of arterial hypertension. Eur. Heart J. 6, 66 (2018).","journal-title":"Eur. Heart J."},{"key":"290_CR15","unstructured":"National Institute on Alcohol Abuse and Alcoholism. Helping Patients Who Drink Too Much: A Clinician\u2019s Guide. Fam Pract News. 2005."},{"key":"290_CR16","doi-asserted-by":"crossref","unstructured":"Prineas R, Crow R, Blackburn H, Prineas R, Crow R, Cow R, et al. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for ECG Measurement in Epidemiologic and Clinical Trials. Springer. 2009.","DOI":"10.1007\/978-1-84882-778-3"},{"key":"290_CR17","unstructured":"R: A language and environment for statistical computing. R Core Team (2019). R Foundation for Statistical Computing, Vienna, Austria. 2019. http:\/\/www.r-project.org"},{"key":"290_CR18","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, 2016). https:\/\/ggplot2.tidyverse.org","DOI":"10.1007\/978-3-319-24277-4"},{"key":"290_CR19","first-page":"66","volume":"6","author":"A Zeileis","year":"2004","unstructured":"Zeileis, A. Econometric computing with HC and HAC covariance matrix estimators. J. Stat. Softw. 6, 66 (2004).","journal-title":"J. Stat. Softw."},{"key":"290_CR20","first-page":"66","volume":"6","author":"A Zeileis","year":"2006","unstructured":"Zeileis, A. Object-oriented computation of sandwich estimators. J. Stat. Softw. 6, 66 (2006).","journal-title":"J. Stat. Softw."},{"key":"290_CR21","first-page":"66","volume":"6","author":"ZM Zhang","year":"2012","unstructured":"Zhang, Z. M., Prineas, R. J., Soliman, E. Z., Baggett, C. & Heiss, G. Prognostic significance of serial Q\/ST-T changes by the Minnesota Code and Novacode in the Atherosclerosis Risk in Communities (ARIC) study. Eur. J. Prev. Cardiol. 6, 66 (2012).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"290_CR22","first-page":"66","volume":"6","author":"EZ Soliman","year":"2015","unstructured":"Soliman, E. Z. et al. Progression of electrocardiographic abnormalities in type 1 diabetes during 16 years of follow-up: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. J. Am. Heart. Assoc. 6, 66 (2015).","journal-title":"J. Am. Heart. Assoc."},{"key":"290_CR23","first-page":"66","volume":"6","author":"LD Rasmussen","year":"2015","unstructured":"Rasmussen, L. D. et al. Myocardial infarction among danish HIV-infected individuals: Population-attributable fractions associated with smoking. Clin. Infect. Dis. 6, 66 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"290_CR24","first-page":"66","volume":"6","author":"R Krittayaphong","year":"2019","unstructured":"Krittayaphong, R. et al. Electrocardiographic predictors of cardiovascular events in patients at high cardiovascular risk: A multicenter study. J. Geriatr. Cardiol. 6, 66 (2019).","journal-title":"J. Geriatr. Cardiol."},{"issue":"6","key":"290_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jelectrocard.2010.10.027","volume":"44","author":"EZEEZ Soliman","year":"2011","unstructured":"Soliman, E. Z. E. E. Z. et al. Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: Results from the strategies for management of antiretroviral therapy study. J Electrocardiol 44(6), 779\u201385 (2011).","journal-title":"J Electrocardiol"},{"key":"290_CR26","first-page":"66","volume":"6","author":"D P\u00e9riard","year":"1999","unstructured":"P\u00e9riard, D. et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 6, 66 (1999).","journal-title":"Circulation"},{"key":"290_CR27","first-page":"66","volume":"6","author":"S Tsiodras","year":"2000","unstructured":"Tsiodras, S., Mantzoros, C., Hammer, S. & Samore, M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch. Intern. Med. 6, 66 (2000).","journal-title":"Arch. Intern. Med."},{"key":"290_CR28","first-page":"66","volume":"6","author":"P Leyes","year":"2018","unstructured":"Leyes, P. et al. Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. AIDS 6, 66 (2018).","journal-title":"AIDS"},{"key":"290_CR29","first-page":"66","volume":"6","author":"JM Gatell","year":"2017","unstructured":"Gatell, J. M. et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS 6, 66 (2017).","journal-title":"AIDS"},{"key":"290_CR30","unstructured":"Knudsen, A. D., Krebs-Demmer, L., Bj\u00f8rge, N., Elming M, Gelpi M, Sigvardsen P, et al. Pericardial Adipose Tissue Volume is Independently Associated with HIV status. Submitt JACC CI."},{"issue":"3","key":"290_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1086\/649897","volume":"201","author":"SW Worm","year":"2010","unstructured":"Worm, S. W. et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 201(3), 318\u201330. https:\/\/doi.org\/10.1086\/649897 (2010).","journal-title":"J. Infect. Dis."},{"key":"290_CR32","first-page":"66","volume":"6","author":"RM Alvi","year":"2018","unstructured":"Alvi, R. M. et al. Protease inhibitors and cardiovascular outcomes in patients with HIV and heart failure. J. Am. Coll. Cardiol. 6, 66 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"290_CR33","unstructured":"European AIDS Clinical Society E. European AIDS Clinical Society Guidelines. Version 10.0. November 2019. IEEE Trans Sonics Ultrason (2019)."},{"key":"290_CR34","first-page":"66","volume":"6","author":"R Bogers","year":"2007","unstructured":"Bogers, R. et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels. Arch Intern Med. 6, 66 (2007).","journal-title":"Arch Intern Med."},{"key":"290_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jamda.2004.12.013","volume":"6","author":"KM Flegal","year":"2005","unstructured":"Flegal, K. M., Graubard, B. I., Williamson, D. F. & Gail, M. H. Excess deaths associated with underweight, overweight, and obesity. J. Am. Med. Assoc. 6, 66 (2005).","journal-title":"J. Am. Med. Assoc."},{"key":"290_CR36","first-page":"66","volume":"6","author":"D Park","year":"2017","unstructured":"Park, D., Lee, J. H. & Han, S. Underweight: Another risk factor for cardiovascular disease?. Medicine 6, 66 (2017).","journal-title":"Medicine"},{"key":"290_CR37","first-page":"66","volume":"6","author":"S Giovinazzo","year":"2019","unstructured":"Giovinazzo, S. et al. Anorexia nervosa and heart disease: a systematic review. Eat. Weight Disord. 6, 66 (2019).","journal-title":"Eat. Weight Disord."},{"key":"290_CR38","unstructured":"Woosley, R., Heise, C., Romero, K. www.crediblemeds.org, QTdrugs List, AZCERT; Inc. 1822 Innovation Park Dr.; Oro Valley; AZ 85755 [Internet]. QTdrugs List. 2020 [cited 2020 Sep 16]. www.Crediblemeds.org"},{"key":"290_CR39","first-page":"66","volume":"6","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib, S. M. et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation 6, 66 (2018).","journal-title":"Circulation"},{"key":"290_CR40","first-page":"66","volume":"6","author":"PE Lazzerini","year":"2021","unstructured":"Lazzerini, P. E. et al. Risk of qtc interval prolongation associated with circulating anti-ro\/ssa antibodies among us veterans: An observational cohort study. J. Am. Heart Assoc. 6, 66 (2021).","journal-title":"J. Am. Heart Assoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00290-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00290-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00290-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:43:31Z","timestamp":1670085811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00290-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["290"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-00290-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"assertion":[{"value":"14 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D.K has received a grant from The Danish Heart Foundation and a travelling grant from Gilead unrelated to this manuscript; LK has received personal fees from AstraZeneca and Novartis as speaker at symposia, unrelated to this manuscript; S.D.N. has received unrestricted research grants from Novo Nordisk Foundation, Lundbeck Foundation, Augustinus Foundation, Rigshospitalet Research Council. Advisory board activity for Gilead and GSK\/ViiV. All unrelated to this manuscript. All other authors report no competing of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20750"}}